Amiodarone increases digoxin levels by 70-100% via P-glycoprotein inhibition, CYP3A4 inhibition, and reduced renal clearance.
Management: Reduce digoxin dose by 50% when initiating amiodarone. Monitor digoxin levels closely.
Amiodarone + diltiazem: additive negative chronotropic and dromotropic effects. Risk of severe bradycardia and AV block.
Management: Avoid combination. If used, continuous ECG monitoring essential.
Amiodarone + beta-blocker: additive bradycardia and AV block. Amiodarone also inhibits beta-blocker metabolism.
Management: If combined, use lowest beta-blocker dose and monitor ECG closely.
Both prolong QT interval via different mechanisms (sotalol: Class III K+ channel; amiodarone: multi-class). Combined use markedly increases torsades de pointes risk.
Management: Avoid combination. If both antiarrhythmics needed, use under cardiologist supervision with continuous ECG monitoring.